Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled, multi-center study of the
safety and efficacy of LibiGel® 300mcg in the treatment of HSDD in surgically menopausal
women